---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-097500"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:28:55.818456+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics Reports Phase 1 CT-0508 Data Showing Safety and Biomarker Correlation

## Summary
- CT-0508 is a HER2-targeted CAR-M therapy for HER2 overexpressing cancers; 14 patients treated across group 1 (n=9) and group 2 (n=5).
- Group 1: best overall response of stable disease in 4 of 9 patients; group 2: best overall response was progressive disease.
- No dose-limiting toxicities reported; CT-0508 well-tolerated after single-day bolus infusion in group 2.
- Translational analyses combining groups show correlation between TME activation, T cell activation, and HER2 status with stable disease.
- Company to focus on combination sub-study with pembrolizumab due to T cell exhaustion findings from trial.

## SEC filing metadata
- accession: 0001104659-23-097500
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923097500/0001104659-23-097500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923097500/tm2325287d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-097500
- JSON: https://secwatch.observer/filing/0001104659-23-097500.json
- Plain text: https://secwatch.observer/filing/0001104659-23-097500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.